caa a22 4500 378898167 CHVBK 20180305123511.0 cr unu---uuuuu 161128e20041201xx s 000 0 eng 10.1515/CCLM.2004.254 doi (NATIONALLICENCE)gruyter-10.1515/CCLM.2004.254 The apoB/apoA-I ratio is better than the cholesterol ratios to estimate the balance between plasma proatherogenic and antiatherogenic lipoproteins and to predict coronary risk [Elektronische Daten] [Göran Walldius, Ingmar Jungner, Are H. Aastveit, Ingar Holme, Curt D. Furberg, Allan D. Sniderman] Background: The apolipoprotein B (apoB)/apoA-I ratio represents the balance of proatherogenic and antiatherogenic lipoproteins. The purpose of this study was to determine whether the apoB/apoA-I ratio was superior to any of the cholesterol ratios - total cholesterol/high-density lipoprotein cholesterol (TC/HDL-C), low-density lipoprotein cholesterol (LDL-C)/HDL-C and non-HDL-C/HDL-C - in predicting the risk of coronary disease. Moreover, we examined whether any lipids, lipoproteins or cholesterol ratios add significant predictive information beyond that provided by the apoB/apoA-I ratio. Methods: Plasma lipids, lipoproteins, apoB, and apoA-I were measured in 69,030 men and 57,168 women above 40years of age. After a mean follow-up of 98months, 1183 men and 560 women had died from a myocardial infarction in this prospective apolipoprotein-related mortality risk (AMORIS) study. Results: High apoB and a high apoB/apoA-I ratio were strongly related to increased coronary risk, while high apoA-I was inversely related to risk. The apoB/apoA-I ratio was superior to any of the cholesterol ratios in predicting risk. This advantage was most pronounced in subjects with LDL-C levels <3.6mmol/l. Addition of lipids, lipoproteins or any cholesterol ratio to apoB/apoA-I in risk models did not further improve the strong predictive value of apoB/apoA-I. Conclusions: These results indicate that the apoB/apoA-I ratio is at present the best single lipoprotein-related variable to quantitate coronary risk. Given the additional advantages apolipoproteins possess - fasting samples are not required, apoB/apoA-I is a better index of the adequacy of statin therapy than LDL-C, and the measurement of apoB and apoA-I are standardized, whereas LDL-C and HDL-C are not - there would appear to be considerable advantage to integrating apolipoproteins into clinical practice. ©2004 by Walter de Gruyter Berlin New York Medical equipment & techniques nationallicence Medical diagnosis nationallicence Diseases & disorders nationallicence apolipoprotein A-I nationallicence apolipoprotein B nationallicence fatal myocardial infarction nationallicence guidelines nationallicence lipoproteins nationallicence Walldius Göran King Gustaf V Research Institute, Karolinska Institute, Stockholm, Sweden and AstraZeneca, Molndal, Sweden aut Jungner Ingmar CALAB Research, Stockholm and Karolinska Institute, Stockholm, Sweden aut Aastveit Are H. Department of Chemistry, Biotechnology and Food Science, Agricultural University of Norway, As, Norway aut Holme Ingar Preventive Medicine Clinic, Ulleval University Hospital, Oslo, Norway aut Furberg Curt D. Wake Forest University School of Medicine, Winston-Salem, NC, USA aut Sniderman Allan D. Mike Rosenblom Laboratory for Cardiovascular Research, McGill University Health Center, McGill University, Montreal, QC, Canada aut Clinical Chemical Laboratory Medicine Walter de Gruyter 42/12(2004-12-01), 1355-1363 1434-6621 42:12<1355 2004 42 cclm https://doi.org/10.1515/CCLM.2004.254 text/html Onlinezugriff via DOI 1 research article jats NATIONALLICENCE 856 40 https://doi.org/10.1515/CCLM.2004.254 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Walldius Göran King Gustaf V Research Institute, Karolinska Institute, Stockholm, Sweden and AstraZeneca, Molndal, Sweden aut NATIONALLICENCE 700 1- Jungner Ingmar CALAB Research, Stockholm and Karolinska Institute, Stockholm, Sweden aut NATIONALLICENCE 700 1- Aastveit Are H. Department of Chemistry, Biotechnology and Food Science, Agricultural University of Norway, As, Norway aut NATIONALLICENCE 700 1- Holme Ingar Preventive Medicine Clinic, Ulleval University Hospital, Oslo, Norway aut NATIONALLICENCE 700 1- Furberg Curt D. Wake Forest University School of Medicine, Winston-Salem, NC, USA aut NATIONALLICENCE 700 1- Sniderman Allan D. Mike Rosenblom Laboratory for Cardiovascular Research, McGill University Health Center, McGill University, Montreal, QC, Canada aut NATIONALLICENCE 773 0- Clinical Chemical Laboratory Medicine Walter de Gruyter 42/12(2004-12-01), 1355-1363 1434-6621 42:12<1355 2004 42 cclm CC0 http://creativecommons.org/publicdomain/zero/1.0 nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-gruyter